TFF Pharmaceuticals, Inc. announced that it has entered into a Collaborative Research and Development Agreement (CRADA) with the National Institute of Environmental Health Sciences (NIEHS) to develop respirable, dry powder formulations of high molecular weight hyaluronan (HMW-HA) for treating or preventing respiratory diseases. Today's agreement follows prior research which showed that HMW-HA formulated with Thin Film Freezing yielded dry powder formulations that possess desirable aerosol performance. Under the terms of the agreement, NIEHS and TFFP will evaluate the pharmacokinetics and therapeutic efficacy of the TFF-HMW-HA formulations using in vitro and in vivo models of select respiratory diseases, with a primary focus on chronic obstructive pulmonary disorder (COPD) and viral respiratory diseases caused by SARS-CoV-2, influenza virus, and/or respiratory syncytial virus (RSV). Other indications may also be explored such as halogen-induced acute lung injury, acute and chronic lung allograft rejection, cystic fibrosis and asthma.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.31 USD | +5.96% | -1.01% | -69.54% |
06:44pm | TFF Pharmaceuticals, Leidos to Advance Biodefense Countermeasures Into Preclinical Testing | MT |
20/05 | TFF Pharmaceuticals Advances Influenza Vaccine Candidates Into Preclinical Testing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-69.54% | 67.54L | |
+64.01% | 6.26TCr | |
-1.26% | 4.12TCr | |
+44.76% | 4.03TCr | |
-8.93% | 2.79TCr | |
+13.43% | 2.62TCr | |
-21.84% | 1.91TCr | |
+4.97% | 1.31TCr | |
+25.22% | 1.23TCr | |
+28.22% | 1.21TCr |
- Stock Market
- Equities
- TFFP Stock
- News TFF Pharmaceuticals, Inc.
- TFF Pharmaceuticals Inc. Enters into Crada with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases